Genmab — August 2012
-
Potential value 1,9 milliarder dollars
-
Janssen aftalen er meget større.
-
nemlig
-
Både Norvartis og Janssen betaler AL forskning
-
significant intererest
-
fra andre selskaber
-
vil lave flere aftaler i fremtiden
-
Duobody er ranked som den bedste bispecifikke antistof platform
-
sammen med Micromet
-
Så dem der skal bygge den næste generation af antistoffer vil vælge Duobody
-
Så er der Dara !
-
snakker lovende om Dara
-
Flere aftaler kan forventes på Duobody btw
-
Partnership expected by year end
-
nemlig aka, og tror de vil blive endnu større hver gang
-
dara dræber cancerceller
-
9 bio in 2020
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind